We are please to announce that OracleBio’s Chief Scientific Officer, Dr. Lorcan Sherry, will be presenting at the 4th International Definiens Symposium to be held in Boston, 13th – 15th May.
Definiens will host more than 20 distinguished speakers at the Symposium, to be held at Joseph B. Martin Conference center on the Harvard Medical School campus. Presenters will highlight how Definiens technology is used in practice to accelerate R&D and discovery of new drugs and biomarkers in automated workflows and how it can be used to innovate new diagnostic tests, increase the success rate of development, reduce time to market and manage the diversity of a broad range of image analysis tasks.
Lorcan’s presentation is entitled ‘Analysis of Drug Response Read-Outs in Xenograft Tissue using Definiens Tissue Studio‘ and will highlight some of OracleBio’s experiences in using Tissue Studio for evaluation of common Xenograft drug response read-outs including evaluation of necrotic and viable tumour regions, proliferation, angiogenesis and biomarker expression. Furthermore, how Tissue Studio can be used to help address specific issues across large batch analysis.